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ABSTRACT
The article is the second part of papers presenting informations useful for an independent analysis of the value 
of published results of clinical trials in oncology. Based on selected examples of clinical trials, a few attempts of 
critical appraisal of clinical trial assumptions, construction, and interpretation of their results are given. Several 
non-inferiority trials are discussed. The paper provides examples of publications in which post hoc analyses, 
grouping of variables, and multiple comparisons were made. Examples of research with a controversial selection 
of patients and a comparator, as well as studies whose clinical significance of the obtained results is questionable 
are presented. The aim of our work is to draw the reader’s attention to selected essential elements of clinical trials 
and the way of presenting their results in order to facilitate practitioners in the independent evaluation of available 
publications and rational use of clinical trial results in everyday practice in the future.
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Introduction
The first part of the publication presented gene-
ral information helpful for independent analysis of the 
value of published results of clinical trials in oncology. 
Unfortunately, the description of the methodology is 
often presented in publications in a very short form, 
and more details can be found only after reading the 
protocol, which is not always available. In addition, the 
time the practitioner can devote to critically evaluate 
a new publication is usually very limited. All this means 
that it is quite difficult for the reader, who is a practitio-
ner rather than a specialist in the field of clinical trial 
methodology, to systematically assess all the elements 
that make up the reliability of a given study, even after 
a very careful reading of the publication resulting from 
a clinical trial. This paper provides practical examples 
of interpretation of selected clinical trials. For obvious 
reasons, the analyses presented cannot be a compre-
hensive assessment of the results of these studies but 
are only an attempt to draw the reader’s attention to 
selected, but in the authors’ opinion very important, 
elements that may affect the interpretation of the pu-
blished results and their impact on clinical practice. 
Non-inferiority studies
Due to a different methodology than that utili-
sed in commonly-used superiority studies, the non-
-inferiority design usually causes inconvenience for 
clinicians. It assesses whether an intervention is not 
inferior, in terms of clinical efficacy, than the current 
standard of treatment. The basic element subjected to 
critical evaluation during interpretation of this type 
of study is the assumed delta value, determining the 
acceptable difference in the clinical effectiveness of 
interventions being compared. It can be defined, for 
159
Piotr Potemski et al., Critical appraisal of clinical trials in oncology — part II
example, by determining the magnitude of maintaining 
the clinical effectiveness of the current treatment stan-
dard, based on the results of a historical study compa-
ring the current standard with symptomatic treatment 
(ASPECCT study) or determining the upper limit of 
the confidence interval based on the value of a clini-
cally acceptable difference of effects adopted as part 
of the consensus (e.g. IDEA study). When interpreting 
the results of this kind of studies, it is worth paying at-
tention to how large differences can be assumed that 
are still considered acceptable.
ASPECCT study
The ASPECCT study was a prospective, non-in-
feriority, phase III clinical trial planned to prove that 
panitumumab monotherapy in patients with metastatic 
colorectal cancer (CRC), who previously received che-
motherapy, could result in at least half of the efficacy 
of cetuximab expressed by increased overall survival 
(OS) as compared to the best supportive care (BSC) 
demonstrated in a historic phase III study [1]. Such 
a defined delta value demonstrating non-inferiority 
seems to be a very safe assumption, which is easy to 
confirm in clinical trial. The study that was referred to 
in this assumption was the CO.17 study, the results of 
which, in a population of patients without KRAS mu-
tation, were published in 2008 [2]. In this study the ha-
zard ratio (HR) for death in the cetuximab group com-
pared to only symptomatic treatment was 0.55 (95% CI 
0.41–0.74), and median OS were 9.5 and 4.8 months, 
respectively. In total, 1010 patients were included in 
the ASPECCT study, and in the first scheduled ana-
lysis the assumption was proven, showing that panitu-
mumab maintained from 81.9 to 129.5% of the effect 
of cetuximab on OS.
IDEA study
The IDEA (International Duration Evaluation 
of Adjuvant Therapy) study is a prospectively plan-
ned, pooled analysis of individual data of patients with 
colon cancer participating in six randomized trials, 
comparing the efficacy of three-month adjuvant oxa-
liplatin chemotherapy (FOLFOX-4 or modified FOL-
FOX-6 or CAPOX) with standard treatment lasting 
half a year [3]. The reason for planning such a study 
was the desire to reduce adjuvant therapy-related to-
xicity (mainly polyneuropathy) that may adversely af-
fect the activity and quality of life of radically treated 
patients. 
The primary endpoint was DFS (disease-free 
survival) in a modified intent-to-treat population 
(randomised patients who received at least one dose 
of chemotherapy), which was achieved by a total of 
12,834 out of 13,025 randomised patients. The delta 
value was set as the upper limit of 95% CI HRDFS of 
1.12. Therefore, if 95% CI HRDFS exceeded 1.12, the 
null hypothesis cannot be rejected, which would mean 
that the shorter duration treatment is worse than the 
assumed value than the standard treatment. According 
to the authors of the study, this delta value was esti-
mated to translate into a predicted reduction in a DFS 
rate after three years by a maximum of 2.7 percentage 
points, and this value was considered acceptable by the 
researchers. As a reminder, in another study in CRC 
(MOSAIC), which established a value of FOLFOX 
adjuvant chemotherapy, patients with stage III disease 
had a DFS rate of 72.2% after three years, compared 
to 65.3% in those receiving fluorouracil with calcium 
folinate [4]. More important, however, is the effect of 
FOLFOX expressed in HRDFS, which in the MOSAIC 
study was 0.76 (95% CI: 0.62–0.92), which means that 
HR for relapse decreased by 24%, and the “true” va-
lue of this reduction (i.e. the value transferred to the 
so-called general population) was between 8% and 
38%. The delta value adopted in the IDEA study cor-
responds to maintaining about 60% of the effect in 
HRDFS found for the comparison of FOLFOX to flu-
orouracil with calcium folinate in patients with stage 
III CRC participating in the MOSAIC study. In the 
IDEA study, according to the randomisation design in 
the primary studies used, interventions were compared 
only for the duration of chemotherapy, but not the type 
of chemotherapy.
In the modified intent-to-treat population HRDFS 
for treatment lasting three months vs. six months amo-
unted to 1.07 (95% CI 1.0–1.15), the assumed value 
of the statistically significant level of p-value for the 
hypothesis of non-inferiority three-month treatment 
was 0.11, and the p-value for the superiority hypothesis 
of six-month treatment was 0.045. This means that the 
primary endpoint was not met, and it was not proven 
(with the adopted delta value) that the shorter treat-
ment is not inferior to the standard one. There are oc-
casionally assessments of the results of this study based 
on numerical values of survival rates after three years 
— 74.6% and 75.5%, respectively. According to this 
assessment, the difference in a DFS rate (0.9 percen-
tage points) is too small to be clinically relevant. This 
interpretation of IDEA research results shows a com-
plete misunderstanding of statistical methodology and 
is entirely incorrect. 
Moreover, pre-planned subgroup analyses were 
of an exploratory nature and cannot be interpreted 
in isolation from primary results of the study. It was 
found that probably the type of chemotherapy (FOL-
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FOX or CAPOX) affects the effectiveness of three-
-month treatment (p for the interaction test was 0.006, 
and after the adjustment for multiple testing it was 
0.02). In the group of 5071 patients receiving CAPOX 
HRDFS amounted to 0.95 (95% CI: 0.85–1.06), which 
would confirm the assumptions of non-inferiority. 
Unfortunately, as previously mentioned, in the inclu-
ded studies no randomisation was made depending on 
the type of chemotherapy, or even randomisation was 
not stratified according to the type of chemotherapy. 
These factors mean that a result related only to the 
CAPOX scheme can be completely accidental, espe-
cially since it is difficult to find medical justification for 
such an observation.
Subgroup analyses and multiple 
comparisons not previously planned
As presented in the first part of the publication, 
randomisation is a very important element of a pro-
perly designed and conducted clinical study. It en-
sures, with a sufficiently large population, an even 
distribution of various, also unknown, confounding 
factors. The lack of randomisation or partial loss of its 
effect, e.g. as a result of post hoc analyses of previously 
unplanned subgroups of patients, means that compa-
red groups may significantly differ in the distribution 
of other significant prognostic features. 
IDEA study
In the IDEA study discussed above, subgroups 
were initially defined depending on the T (T1–3 and 
T4) and N (N1 and N2) feature, and none of the as-
sumptions of non-inferiority of treatment lasting three 
months were shown in any of them. However, when 
analysing post hoc results, two categories of recurrence 
risk were created: low (T1–3N1) and high (T4 or N2). 
In the low-risk category (7471 patients) the assumption 
of non-inferiority regardless of the type of chemothe-
rapy was confirmed at borderline (HRDFS = 1.01, 95% 
CI: 0.90–1.12); similarly it was confirmed in the group 
of patients (N = 2,852) receiving CAPOX and classi-
fied as low risk (HRDFS = 0.85, 95% CI: 0.71–1.01). In 
all other groups, i.e. high risk, regardless of the type of 
chemotherapy, or FOLFOX-treated low-risk patients, 
non-inferiority assumptions could not be demonstra-
ted. It should be taken into account that the evaluation 
depending on these categories was not planned before, 
and it was performed only after analysing the obtained 
results. This means that in these subgroups the unk-
nown additional factors may play an important role, 
and due to this the results of post hoc analyses can-
not be considered as formal proofs used to infer real 
differences in the effectiveness of interventions. In the 
opinion of the authors of this work, the only potential-
ly useful suggestion resulting from these analyses may 
be the possibility to shorten the duration of CAPOX 
chemotherapy to three months in patients with T1–
–3N1 CRC in the case of poor treatment tolerance, as 
an alternative to reducing the oxaliplatin dose or its 
withdrawal and continuing therapy with fluoropyrimi-
dine alone.
ASPECCT study
Even better, the problem of multiple compari-
sons and random results considered “statistically sig-
nificant” is illustrated in an article published in 2016, 
which presents the updated results of the ASPECCT 
study and, among others, post hoc analysis depending 
on previous treatment with bevacizumab [5]. It was 
found that in a group of 258 patients who were pre-
viously treated with bevacizumab OS was longer when 
they received panitumumab, not cetuximab. Medians 
OS were 11.3 and 9.8 months, respectively (HR = 0.75, 
95% CI: 0.58–0.97). This observation has led to at-
tempts to promote panitumumab rather than cetuxi-
mab as the drug of choice in patients previously expo-
sed to bevacizumab. This raises the question of how to 
explain the advantage of panitumumab over cetuximab 
in individuals who have previously been treated with 
bevacizumab, when the biological mechanism of action 
of both drugs is very similar. This is a good example of 
misinterpretation of observation results, the nature of 
which is probably accidental and should not be the ba-
sis for a change in clinical practice. Obviously, in such 
situations, the statistically significant p-value should be 
lower than the usual one (< 0.05) because it must take 
into account unplanned hypothesis multiple testing 
used in post hoc analyses (Bonferroni correction). 
Presenting the results of previously unplanned 
comparisons means that many similar ones were most 
probably carried out in other subgroups, but only some 
of them were selected because the more post hoc ana-
lyses are carried out, the more likely it is that the out-
come of any of them will be completely randomly “sta-
tistically significant”. 
A study “showing” the importance of the 
astrological zodiac signs in medicine
Very instructive examples of the apparent demon-
stration of non-existent relationships are two works pu-
blished by their authors just to show readers the dan-
gers resulting from making multiple comparisons and 
grouping post hoc variables [6, 7]. 
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In the first one, the relationships between astro-
logical zodiac signs and the 223 most frequent reasons 
for hospitalisation of the inhabitants of Canada were 
evaluated [6]. A group of over 10 million people was 
randomly divided into two groups: a cohort in which 
possible relationships were tested and an indepen-
dent validation cohort. Two zodiac signs were found 
to be associated with a higher risk of hospitalisation 
compared to the remaining 10. In the validation co-
hort, the relationship between the two signs and the 
individual causes of hospitalisation was examined, and 
it was found that people born under the sign of Leo 
were significantly more frequently (p = 0.0447) hospi-
talised due to gastrointestinal bleeding, and those born 
under the sign of Sagittarius significantly more often 
(p = 0.0123) due to humerus fracture, compared to 
people born under the other signs of the zodiac. Obvio-
usly, after introducing adjustment for multiple testing, 
these apparent relationships disappeared.
Another study investigated the relationship be-
tween the zodiac sign and prognosis after myeloabla-
tive chemotherapy and allogenic haematopoietic stem 
cell transplantation in patients with chronic myeloge-
nous leukaemia [7]. The survival probabilities of at le-
ast five years were analysed in a group of 626 patients 
depending on their zodiac sign, and numerical but not 
statistically significant differences were found. Howe-
ver, when individuals born under the sign of Aries, 
Taurus, Gemini, Leo, Scorpio, or Capricorn (a total 
of 317 patients) were separated and compared with 
the remaining group (309 patients), the difference was 
statistically significant (five-year survival 58% vs. 48%; 
p = 0.007). Moreover, after a multivariate analysis that 
took into account the possible impact of other known 
prognostic factors, the results of treatment of patients 
born under one of the zodiac signs mentioned above 
were still significantly better than in the remaining pa-
tients (p = 0.005). The authors concluded that this is 
an example of “proving” a non-existent correlation, 
and the observed “significant” dependencies are the 
result of grouping post hoc variables in order to obtain 
the greatest and “statistically significant” difference.
COU-AA-302 study
An example of a proper interpretation of the po-
ssible impact of multiple testing in relation to survi-
val outcomes is the adoption of another threshold of 
statistical significance for the results of pre-planned, 
stepwise analyses of randomised clinical trials. For 
example, in the phase III COU-AA-302 study, which 
compared abiraterone acetate in combination with 
prednisone to placebo-prednisone combination in 
patients with metastatic castration-resistant prostate 
cancer not previously treated with docetaxel, the two 
primary endpoints were: radiographic progression-free 
survival (rPFS) and OS. A typical p-value of 0.05 was 
therefore divided into both endpoints by default — the 
statistical significance of the difference in rPFS requ-
ired that the p-value should be less than 0.01, and in 
the case of OS — less than 0.04 [8]. 
It was planned that the OS assessment would be 
conducted in several stages (interim analyses) — after 
the occurrence of 15%, 40%, and 55% of the number 
of deaths required for the final analysis, respective-
ly, and final analysis after the occurrence of at least 
773 deaths (1,088 patients were included in the study). 
Due to multiple testing of drug effects on OS (with 
data cut-offs at different time points), the correction of 
borderline p-values required to establish statistical sig-
nificance found in these stepwise analyses of differen-
ces was applied in accordance with the procedure de-
scribed by O’Brian and Fleming. The first publication 
contained the final result of the rPFS analysis, which 
found a statistically significant difference between abi-
raterone and placebo (HR = 0.55, 95% CI: 0.45–0.62, 
p < 0.001) and the result of interim OS analysis after 
43% of the required 773 events. It was found that the 
HROS was 0.75 (95% CI: 0.61–0.93, p = 0.01). Altho-
ugh the p-value was less than the required 0.04, only 
the adjusted p-value of 0.001 or less was determined 
to indicate the statistical significance of the OS diffe-
rence in this stepwise analysis. The result of the next 
published interim analysis carried out after 56% of de-
aths was also not statistically significant (HR = 0.79, 
95% CI: 0.66–0.95, p = 0.0151, required adjusted 
p-value = 0.0035) [9]. Only the final OS analysis after 
96% of the 773 deaths revealed the effect of the drug 
on OS prolongation (HR 0.81, 95% CI 0.70–0.93, 
p = 0.0033), i.e. it was allowed to meet the second co-
-primary endpoint [10]. 
Selection of patients and comparators
The correct patient selection, appropriate to 
carry out the planned intervention, is an indispensa-
ble element of a well-designed and conducted study, 
and also allows extrapolation of the outcomes to a po-
pulation that will be treated in real-life clinical prac-
tice. The use of a proper comparator, which is a key 
element of a well-conducted clinical trial, implies the 
use of therapy that is consistent with current clinical 
practice and generally accepted recommendations and 
guidelines, including their continuous evolution, espe-
cially in a field developing as rapidly as oncology. In-
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appropriate selection, contrary to commonly accepted 
recommendations, makes it impossible to accept study 
conclusions as reliable (external credibility). An exam-
ple of a recently published trial with highly controver-
sial patient selection is the CARMENA study.
CARMENA study
The aim of the non-inferiority phase III CAR-
MENA (Cancer du Rein Metastatique Nephrectomie 
et Antiangiogéniques) study published in 2018 was 
to show that not performing nephrectomy in patients 
with metastatic renal cell carcinoma (mRCC) prior 
to sunitinib treatment is not inferior to such therapy 
with previous nephrectomy [11]. The primary endpo-
int was OS, and randomisation was stratified, among 
others, by prognostic categories. The results of the 
CARMENA study are fairly widely interpreted as be-
ing likely to change clinical practice, as it has been 
shown that not performing cytoreductive nephrecto-
my is non-inferior (HROS = 0.89; 95% CI: 0.71–1.10; 
non-inferiority criterion: upper limit of 95% CI not 
higher than 1.20). 
However, while analysing the significance of the 
obtained result and its potential impact on clinical prac-
tice, the key limitation of this study should be remem-
bered, which was the selection of patients. The study 
included patients meeting the criteria of intermediate 
or poor prognosis according to the MSKCC (Memorial 
Sloan Kettering Cancer Centre), and as many as 43% 
of patients participating in CARMENA study were as-
signed to the category of unfavourable prognosis. Until 
recently, in patients included in the category of unfa-
vourable prognosis, the only drug for which phase III 
study showed a slight effect on OS prolongation was 
temsirolimus, a drug currently being reimbursed in 
such patients, also in Poland [12]. There are also no 
reliable data from a randomised study confirming the 
effect of sunitinib, used in CARMENA study, on OS 
in patients with unfavourable prognosis. In addition, 
nephrectomy is generally not performed or recommen-
ded in such patients, and in the aforementioned phase 
III study with temsirolimus, no beneficial effect of this 
procedure (sometimes performed a long time prior to 
randomisation) was observed on the efficacy of mTOR 
inhibitor. For these reasons, allowing inclusion in the 
study assessing the impact of abandoning nephrectomy 
the patients with poor prognosis category and treating 
them with sunitinib should be considered as not justi-
fied by existing medical knowledge. The use of suniti-
nib but not temsirolimus in some centres in patients 
with poor prognosis cannot be considered as practice 
in line with Evidence-Based Medicine. 
The results of the CARMENA study were obta-
ined in all patients enrolled, and those with an unfa-
vourable prognosis had a significant influence on the 
final study results. In this group of patients neither ne-
phrectomy nor sunitinib could affect the primary end-
point. With this assumption, it would not be difficult to 
prove non-inferiority of not performing nephrectomy 
in high-risk patients. An indication that seems to sup-
port this hypothesis may be the results for each pro-
gnostic group separately. In the group of unfavourable 
and intermediate prognosis, HROS were 0.86 (95% CI: 
0.62–1.17) and 0.92 (95% CI: 0.68–1.24), respectively. 
As can be seen, only in the unfavourable prognosis 
group did the obtained result meet the accepted non-
-inferiority criterion (upper limit of 95% CI not greater 
than 1.20). Obviously, this cannot be considered as evi-
dence but only a premise indicating the correctness of 
the given interpretation.
The statistical analysis carried out in the intent-
-to-treat (ITT) population assumes the evaluation of 
the results of all randomised patients, regardless of 
whether they received the assigned intervention or not. 
The interpretation of the result of the CARMENA 
study should also take into account the fact that 16 pa-
tients in the group of 226 included in the nephrectomy 
arm (7%) did not have it, and 38 of 224 subjects ran-
domised to the arm with only systemic therapy (17%) 
underwent nephrectomy. This reduces the differences 
between the arms and facilitates the demonstration of 
non-inferiority in the ITT population. Finally, the ori-
ginal plan assumed the inclusion of 576 patients and 
the evaluation after 452 deaths, but as a result of the 
unsatisfactory recruitment rate the study was disconti-
nued after including 450 patients, and the final results 
were published after the occurrence of 326 deaths.
CheckMate 214 study
The problem of selection of the comparator and 
target population was also encountered in the phase 
III CheckMate 214 study, in which the combination 
of nivolumab with ipilimumab in patients with mRCC 
was evaluated, and sunitinib was used as a comparator 
[13]. Whereas in the case of patients with a favourable 
or intermediate prognosis such a comparator does not 
raise any doubts; in the case of patients included in the 
category of unfavourable prognosis it is difficult — for 
reasons discussed earlier — to be considered as opti-
mal. Such patients accounted for as much as 21% of 
the population in which the primary endpoints were as-
sessed, i.e. objective response rate, PFS, and OS. The 
p-value of the statistical significance 0.05 was divided 
into: 0.001 (objective response rate), 0.009 (PFS), and 
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0.04 (OS). Patients were included in the study regar-
dless of the prognostic category, but the assessment of 
primary endpoints was only planned for patients with 
an intermediate or unfavourable prognosis. Secondary 
endpoints included: objective response rate (ORR), 
PFS and OS in randomized patients (IT population), 
and the frequency of adverse events in patients who 
received treatment. An exploratory analysis was plan-
ned only in a group of 249 patients with a favourable 
prognosis (21% of the randomised population).
Regarding the primary endpoints, there were dif-
ferences in ORR and OS in favour of immunotherapy, 
but not in PFS (p = 0.03). In the randomised popu-
lation, no significant difference was found in any of 
the three secondary efficacy endpoints. This means 
that the inclusion of patients from the favourable pro-
gnosis group abolished the beneficial effect of immu-
notherapy with respect to response rate and OS. The 
results of an exploratory efficacy analysis in a favoura-
ble prognostic group are very worrying — there has 
been a reversal of the influence of immunotherapy and 
comparator to the detriment of experimental treat-
ment. The response rate was 29% vs. 52% (p < 0.001), 
HRPFS = 2.18 (p < 0.001), and HROS = 1.45 (p = 0.27, 
with only 37 deaths). 
An obvious interpretation of the study results in-
dicates that the benefit of immunotherapy is limited 
only to patients in the intermediate or poor prognosis 
category (with explicit reservation regarding external 
reliability due to the use of a suboptimal comparator 
in the latter group). However, it should be noted that 
only one of the six factors of unfavourable prognosis 
according to the International Metastatic Renal Car-
cinoma Database Consortium (IMDC) classification: 
Karnofsky performance status 70, time from diagnosis 
of cancer to randomisation shorter than one year, ana-
emia, corrected calcium concentration in serum above 
10 mg/dl, neutrophilic granulocytosis, and thrombocy-
thaemia, was associated with a benefit in immunothe-
rapy. Inevitable doubts therefore arise as to whether 
this relationship is true for each of these mentioned 
factors that are so different, and whether the benefit 
of immunotherapy depends on the number of poor 
prognosis factors. Unfortunately, the publication of 
CheckMate 214 results does give any answers these 
question. Among 667 patients belonging to the inter-
mediate-risk group, no analyses were performed that 
could clarify these doubts. 
Another surprising choice was the use of only 
a combination of anti-CTLA4 and anti-PD1 antibody 
in the experimental arm, but not anti-PD1 monothera-
py. This could be due to the desire to obtain the best 
direct effect (ORR was one of the primary endpoints). 
This does not undermine the value of the combination 
itself, but raises the question, however, of whether anti-
-PD1 monotherapy would not be equally effective and 
less toxic as well. This question can be considered as 
justified especially in the context of the final results of 
the previously launched CheckMate 025 study, publi-
shed at the end of 2015, in which in previously treated 
patients nivolumab was used with good results. Such 
a doubt was raised by the European Medicines Agency 
(EMA) Committee for Medicinal Products for Human 
Use (CHMP) as justification for a surprising prima-
ry negative opinion regarding the registration of this 
combination in patients with kidney cancer.
SOLO3 study
It is also bewildering to select a comparator in 
the ongoing phase III SOLO3 study, in which olaparib 
is compared to single-agent chemotherapy in women 
with recurrent (at least two earlier lines of chemothe-
rapy containing a platinum compound) still platinum-
-sensitive (progression later than six months after the 
end of the last chemotherapy) ovarian cancer with the 
presence of germline BRCA mutation [14]. The plan-
ned primary study endpoint is ORR. The comparator 
is the investigator’s choice between paclitaxel, liposo-
mal doxorubicin, topotecan, and gemcitabine. 
As a reminder, a commonly accepted standard 
treatment for such patients is platinum-based chemo-
therapy and not monotherapy with any of the drugs 
mentioned above. In addition, the choice of the pri-
mary endpoint is also difficult to consider to be ap-
propriate and clinically important. Considering these 
reservations, it is difficult to imagine that the result of 
this study could be useful in clinical practice.
20100007 study
If the use of placebo, or only BSC, as a comparator 
is common practice when there is no other therapeutic 
option with proven efficacy (usually the last treatment 
line), or the intervention tested and placebo as a com-
parator are added to the current standard (add-on), 
the use of placebo or only BSC in a situation where 
there are other therapies with previously demonstra-
ted efficacy should always raise ethical concerns. The 
aim of this phase III study published in 2016 was to 
demonstrate that panitumumab affects OS prolonga-
tion compared to BSC in previously systemically tre-
ated patients with metastatic CRC without mutation in 
exon 2 of the KRAS gene [15]. There would be nothing 
surprising in the study design if not for the fact that 
the recruitment of patients was carried out between 
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November 2011 and July 2013, offering BSC as a com-
parator. This contradicted common knowledge about 
the efficacy of cetuximab in the treatment of patients 
with metastatic CRC. In the phase III study published 
in 2007 (the recruitment started in January 2004) and 
in which the value of panitumumab was for the first 
time evaluated in comparison to BSC, the authors hi-
ghlighted that the project assumed from the beginning 
the possibility of changing the study arm in the control 
group after disease progression (cross-over) due to the 
“previously known activity of panitumumab and cetu-
ximab” [16]. In addition, the design of this study with 
PFS as the primary endpoint and assumed cross-over 
meant that during the registration, the manufacturer 
was required to plan and conduct a non-inferiority stu-
dy comparing panitumumab with cetuximab, because 
since 2007 the effect of cetuximab on OS prolongation 
has been known in comparison to BSC. Both antibo-
dies, i.e. panitumumab and cetuximab, have been re-
gistered for the treatment of patients with chemoresi-
stant metastatic CRC by both the US Food and Drug 
Administration and the EMA. In the European Union 
cetuximab was authorised in 2004 and panitumumab in 
2007 (already taking into account the state of the KRAS 
gene). In 2008, the registration of cetuximab was modi-
fied, taking into account the state of the KRAS gene. In 
February 2010, recruitment to the previously discussed 
non-inferiority ASPECCT study was started, in which 
OS was the primary endpoint. How then, a few years 
after the first registration of both drugs, was it possible 
to conduct a clinical trial in which half of the patients 
included in the study received only BSC or a subop-
timal procedure? Obviously, in the 20100007 study 
cross-over to panitumumab in the control group after 
disease progression was not assumed, and yet such an 
option was in the study, which was conducted during 
the period when there was no data confirming the ef-
fect of anti-EGFR drugs on OS. 
Is every statistically significant 
difference also clinically relevant?
An element of critical evaluation of clinical trials 
in oncology should always be an answer to the question 
of whether the statistical significance obtained in a stu-
dy is of practical significance and whether it is enough 
to change clinical practice. This issue raises a lot of 
controversy, because the assessment of how much of 
the benefit from a PFS or OS extension can be conside-
red clinically relevant is extremely subjective. The di-
scussion about this began, among other things, because 
there was a tendency to design commercial studies car-
ried out on very large groups of patients, in which very 
small differences in efficacy could be demonstrated, 
but still achieving a level of statistical significance. Ta-
king into account the fact that the primary endpoint of 
these studies was PFS, it was difficult to translate these 
results into clinical practice, especially considering the 
higher toxicity and significant cost of new drugs.
NCIC CTG PA.3 and VELOUR studies
The phase III NCIC CTG PA.3 study showed 
that the combination of gemcitabine and erlotinib in 
patients with advanced pancreatic cancer statistically 
significantly prolongs OS [17]. Although it was the first 
phase III study indicating advantage of combining gem-
citabine with another drug, a fairly common percep-
tion of the clinical relevance of this study was far from 
enthusiastic, and this study became a classic example 
of a statistically significant but clinically meaningless 
result. The reason for this was primarily the low nume-
rical difference in OS — HR had a value of 0.82 (95% 
CI: 0.69–0.99), the median OS 6.24 vs. 5.91 months, 
and 12-month survival rate was 23% vs. 17%. The large 
number of patients included in the study (569 people) 
meant that the absolute difference in the number of 
deaths between the arms of eight cases translated into 
statistical significance in the log-rank test. Especially 
underlined by the commentators was the difference in 
medians amounting to only 0.33 months. In addition, 
an increased frequency of some adverse events, e.g. 
diarrhoea and skin lesions, was observed in the expe-
rimental arm.
Assessment of the NCIC CTG PA.3 study va-
lue tested only from the perspective of difference in 
medians, although easy to communicate, is obviously 
somewhat simplified because it covers only one time 
point on survival curves. A better, although non-intu-
itive, measure is HR for death, in which an 18% re-
duction is already more clinically promising. For com-
parison, aflibercept, a drug currently being reimbursed 
in Poland in second-line treatment for patients with 
metastatic CRC added to FOLFIRI chemotherapy 
regimen in the phase III VELOR study, reduced HR 
for death by 18% (HR 0.817, 95% CI 0.713–0.937). 
The difference in medians was 1.44 months, and the 
probability of 24-month survival was 28% vs. 19% [18]. 
Demonstration that such a difference is statistically 
significant at the p level of 0.0032 was possible due to 
the inclusion of up to 1,226 patients in the study. Then, 
several reports were published to dispel doubts as to 
whether the difference in prognosis found in the VE-
LOUR study is clinically relevant. One year after the 
original publication, extrapolating the obtained data 
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beyond the duration of the study using mathematical 
methods, the mean survival times of patients from both 
arms were estimated in the perspective of 15 years, sta-
ting that the difference between them is 4.7 months, 
which seems to have made an improved impression 
on the readers of that time than the difference in me-
dians of 1.44 months [19]. Another attempt, the result 
of which was announced in print in 2014, consisted 
of making post hoc analyses and, as a result, extrac-
ting the subgroups referring to the “greater” benefit 
from experimental treatment [20]. It was found that 
patients in very good performance status (PS 0) with 
any number of distant metastases and patients in good 
condition (PS 1) having metastasis only in one loca-
tion have a median OS greater by 3.1 months if they 
received aflibercept. Obviously, such analyses can ge-
nerate research hypotheses, but certainly they do not 
allow the transfer of the results obtained in this way to 
the so-called general population. The value of post hoc 
analyses based on variable grouping has already been 
discussed in this article. It should be mentioned here 
that such actions are unfortunately used to obtain the 
greatest possible difference in the median of survival, 
which facilitates obtaining more favourable results of 
the cost-effectiveness analysis carried out as part of the 
process of reimbursement application. It is very likely 
that the subgroups extracted in this manner may not 
have any real predictive value. 
NO16966 study
An example of a study that, at least some coun-
tries (e.g. in the USA), influenced the change of clini-
cal practice despite seriously doubting the real value 
of the obtained results, was a phase III trial evaluating 
the benefit of adding bevacizumab to oxaliplatin-con-
taining chemotherapy in the first line of treatment of 
patients with metastatic CRC [21]. The primary end-
point was PFS, and patients who received either FOL-
FOX-4 or XELOX chemotherapy with bevacizumab 
showed longer PFS (HR = 0.83, 95% CI: 0.72–0.95, 
median PFS: 9.4 vs. 8.0 months). The difference was 
statistically significant at p value = 0.0023, and it was 
possible to demonstrate it due to the sample size of 
1,401 patients. Naturally, there was no OS benefit due 
to the use of antibody. 
Doubts about the clinical significance of the re-
sults of some studies are the reason that ESMO (Euro-
pean Society for Medical Oncology) proposed the va-
lues of differences in individual endpoints depending, 
among others, on a prognosis that may be considered 
clinically significant [22]. The review of randomised 
clinical trials published between 2011 and 2015 regar-
ding systemic treatment of patients with breast cancer, 
NSCLC, CRC, or pancreatic cancer included 277 stu-
dies [23]. In 138 of these studies, statistically signifi-
cant differences between experimental therapy and the 
comparator were presented; however, after using the 
ESMO criteria of clinical significance, the results only 
43 (31%) out of 138 studies were considered to be sta-
tistically significant. 
Summary
In this analysis, the authors focused on selected 
issues, illustrating them with examples of specific cli-
nical trials. Non-inferiority studies have been discus-
sed because this type of clinical trial usually poses 
a lot of problems to readers, which is associated with 
a completely different methodology compared to stu-
dies that aim to demonstrate the superiority of one 
intervention over another. Examples of publications 
with post hoc analyses, grouping of variables, and 
multiple comparisons are given. Examples of clinical 
trials are presented, understanding and interpreta-
tion of which are impossible without paying attention 
to doubts about the characteristics of patients being 
included or the selection of a comparator. An extre-
me example of research with results that are difficult 
to transfer to clinical practice are those in which the 
control group is treated suboptimally, i.e. less effecti-
vely than is possible. Fortunately, there are not many 
of such studies, but more often there are clinical 
trials in which doubts relate to some of the patients 
included in them. Finally, examples of studies raising 
doubts about the so-called clinical relevance of the 
results obtained are given. 
The authors hope that two publications prepared 
in cooperation of medical statisticians and oncologists 
will make easier for readers to interpret the available 
publications and thus rationally use the results of clini-
cal trials in everyday practice.
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